Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moon-Hee Lee

Showing results (121-130 of 133) with videos related to

Pageof 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02Yeon Hee Park, Kyung Hae Jung, Seock-Ah Im, et al.
Cancer Research and Treatment|November 18, 2022
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)Dae-Won Lee, Bhumsuk Keam, Keun Seok Lee, et al.
Expert Opinion on Biological Therapy|April 26, 2024
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance studyMin Ho Park, Jae Hong Seo, Jung Ho Park, et al.
Cancer Research and Treatment|December 4, 2009
Randomized, multi-center phase II trial of docetaxel plus cisplatin versus etoposide plus cisplatin as the first-line therapy for patients with advanced non-small cell lung cancerNam-Su Lee, Hee-Sook Park, Jong-Ho Won, et al.
Oncology Reports|July 14, 2005
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factorSeock-Ah Im, Sung-Bae Kim, Moon Hee Lee, et al.
The Lancet. Oncology|November 1, 2019
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trialYeon Hee Park, Tae-Yong Kim, Gun Min Kim, et al.
Breast Cancer Research and Treatment|June 3, 2015
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)Yeon Hee Park, Kyung Hae Jung, Seock-Ah Im, et al.
The Lancet. Oncology|February 20, 2025
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 studyHee Kyung Ahn, Ji-Yeon Kim, Kyung-Hun Lee, et al.
BMC Cancer|August 10, 2025
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)Jieun Lee, Hee Kyung Ahn, Kyung-Hun Lee, et al.
Anticancer Research|December 30, 2023
Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational StudyJwa Hoon Kim, Yongjun Cha, Sang Joon Shin, et al.
Pageof 14

Showing results (121-130 of 133) with videos related to

Sort By:
Pageof 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02Yeon Hee Park, Kyung Hae Jung, Seock-Ah Im, et al.
Cancer Research and Treatment|November 18, 2022
A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)Dae-Won Lee, Bhumsuk Keam, Keun Seok Lee, et al.
Expert Opinion on Biological Therapy|April 26, 2024
Efficacy and safety of biosimilar trastuzumab (CT-P6) in routine clinical practice in the Republic of Korea: a real-world post-marketing surveillance studyMin Ho Park, Jae Hong Seo, Jung Ho Park, et al.
Cancer Research and Treatment|December 4, 2009
Randomized, multi-center phase II trial of docetaxel plus cisplatin versus etoposide plus cisplatin as the first-line therapy for patients with advanced non-small cell lung cancerNam-Su Lee, Hee-Sook Park, Jong-Ho Won, et al.
Oncology Reports|July 14, 2005
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factorSeock-Ah Im, Sung-Bae Kim, Moon Hee Lee, et al.
The Lancet. Oncology|November 1, 2019
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trialYeon Hee Park, Tae-Yong Kim, Gun Min Kim, et al.
Breast Cancer Research and Treatment|June 3, 2015
Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02)Yeon Hee Park, Kyung Hae Jung, Seock-Ah Im, et al.
The Lancet. Oncology|February 20, 2025
Palbociclib plus endocrine therapy versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (Young-PEARL): overall survival analysis of a randomised, open-label, phase 2 studyHee Kyung Ahn, Ji-Yeon Kim, Kyung-Hun Lee, et al.
BMC Cancer|August 10, 2025
Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)Jieun Lee, Hee Kyung Ahn, Kyung-Hun Lee, et al.
Anticancer Research|December 30, 2023
Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational StudyJwa Hoon Kim, Yongjun Cha, Sang Joon Shin, et al.
Pageof 14